KUALA LUMPUR, July 28 (Bernama) -- George Clinical recognised and applauded its collaborative partner Omico, with whom it is aligned in a common goal to revolutionise oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark programme PrOSPeCT.
According to George Clinical in a statement, PrOSPeCT is a programme that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products.
Omico is an Australian government-backed national network of leading researchers, clinicians and industry partners, including George Clinical, that are using precision medicine to unlock new potential in Australian research and turn the tide on cancer.
With fast-tracked molecular screening, biomarker-led trial set up and patient enrolment across the entire nation, Omico is accelerating access to next-generation treatments and preventive strategies improving outcomes for all Australians affected by cancer.
Through the PrOSPeCT initiative, Omico is further expanding its reach by opening up new treatment paths across Australia for people with difficult-to-treat cancers including those with ovarian cancers, pancreatic cancers, sarcomas, and advanced and metastatic cancers.
PrOSPeCT aims to screen a magnitude of patients that is beneficial to the Australian public and the economy with 23,000 patients to access free, cutting edge genomic screening.
The programme also aims to match patients to precision medicines in clinical trials that are being conducted across Australia and to create a database of real-world data that will be useful in the future for further research.
A global clinical research organisation founded in Asia Pacific, George Clinical’s success with oncology trials has been driven by scientific expertise and operational excellence.
-- BERNAMA
No comments:
Post a Comment